Clinical Trial Update: Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating memantine, an NMDA receptor blocker, for inhibiting α-synuclein cell-to-cell transmission in Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Wayne State University | Conditions: Parkinson Disease | Phase 3 | Status: UNKNOWN